Over-expression of SRD5A3 and its prognostic significance in breast cancer

• Published in: World journal of surgical oncology 2021-08, Vol.19 (1), p.260-260, Article 260
• Main Authors: Zhang, Yong-Ping, Na, Wen-Ting, Dai, Xiao-Qiang, Li, Ruo-Fei, Wang, Jian-Xiong, Gao, Ting, Zhang, Wei-Bo, Xiang, Cheng
• Format: Article
• Language: English
• Subjects: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics; Bioinformatics; Biomarkers; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - genetics; Cancer therapies; Care and treatment; Computational Biology; Data mining; Diagnosis; Evaluation; Female; Gene expression; Gene Ontology; Humans; Localization; Medical prognosis; Membrane Proteins - genetics; Metabolism; Methods; Mutation; Overexpression; Patients; Prognosis; Protein expression; Proteins; Reductases; Regression analysis; RNA, Messenger - genetics; Software; SRD5A3 expression; Steroids; Survival; Survival analysis; Therapeutic targets; Tumors
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-021-02377-1

The study aimed to compare the Steroid 5 alpha-reductase 3 (SRD5A3) expression levels in breast cancer (BC) and normal tissues, to investigate the prognostic value of SRD5A3 mRNA expression in BC patients and to identify the SRD5A3-related signaling pathways using bioinformatics approaches. We evaluated the expression levels of SRD5A3 and survival data in BC patients using different bioinformatic databases. Further, Cox regression analysis was conducted to predict the independent prognostic factors for BC. Moreover, the association of SRD5A3 with clinicopathological factors was measured through LinkedOmics database. And the potential role of SRD5A3 was determined by Gene Ontology and KEGG pathway enrichment analysis. Finally, protein network of SRD5A3 was constructed and genetic alterations were analyzed. Bioinformatic data indicated that both mRNA and protein expression levels of SRD5A3 were higher in BC group than those in the normal group (P < 0.05). Besides, BC patients with higher SRD5A3 mRNA expression levels had a lower overall survival (all P < 0.05). Cox regression analysis further demonstrated the independent prognostic value of SRD5A3 in BC (P = 0.015). SRD5A3 mRNA expression was significantly associated with N stage (P < 0.001), age (P < 0.05), and histologic subtype (P < 0.001) but had no significant relationship with other clinical characteristics (all P > 0.05). Moreover, the functional enrichment analysis revealed that the SRD5A3 was involved in metabolism-related pathways (all P < 0.05). SRD5A3 was highly expressed in BC tissues and high SRD5A3 expression was related to poorer prognosis. SRD5A3 serves as an oncogene and might function as a potential biomarker for prognosis and a therapeutic target for BC.